Figures & data
Table 1. Patient characteristics.
Figure 1. Expression and impact on survival of carbonic anhydrase IX. (A) Immunohistochemistry: Representative images of carbonic anhydrase IX positive and negative immunohistochemical staining of neuroblastoma tissue are shown (20× standard microscopic enlargement). (B) Overall survival: For the Kaplan-Meier survival analysis, patients were grouped according to positive and negative carbonic anhydrase IX expression. Overall survival of neuroblastoma patients with no carbonic anhydrase IX expression was significantly better than that of carbonic anhydrase IX positive patients (p = 0.015).
Figure 2. Carbonic anhydrase IX RNA expression under normoxic and hypoxic conditions in Kelly and SH-EP Tet-21/N neuroblastoma cells. Major increase of carbonic anhydrase IX RNA expression under hypoxic conditions in Kelly and Tet neuroblastoma cells with respect to normoxic conditions.
Figure 3. Proliferation of Kelly and SH-EP Tet-21/N neuroblastoma cells under treatment with carbonic anhydrase IX inhibitors FC5-207A and FC8-325A. (A) A significant reduction of proliferation can be observed for both inhibitors under normoxia (FC5-207A: p = 0.022; FC8-325A: p < 0.001) and even more strongly under hypoxic conditions (FC5-207A: p = 0.004; FC8-325A: p < 0.001) compared to the control in Kelly cells. (B) A significant reduction of proliferation could only be observed for substance FC8-325A (normoxia: p < 0.001; hypoxia: p < 0.001). Differences between the control and substance FC5-207A were not significant. (C) Chemical structures of carbonic anhydrase inhibitors FC5-207A and FC8-325A.
